Zhejiang Yongning Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is a pharmaceutical enterprise mainly engaged in the research and development and production of innovative drugs and preparations. It is a national high-tech enterprise, an innovative pilot enterprise and a patent demonstration enterprise in Zhejiang Province.
Founded in 1974, the company is the first industrial enterprise in Taizhou with an annual sales of more than 100 million yuan. It was restructured into a joint-stock enterprise in 2007, with a registered capital of 153.125 million yuan and a warehousing tax of more than 100 million yuan. It is a "large taxpayer in Zhejiang Province", covering 140000 square meters, and has more than 1300 employees, including 50 masters, 6 doctors, more than 300 professional and technical personnel, 23 people with senior professional titles. It has more than 100 products in five categories, including chemical preparations, chemical pharmaceutical intermediates, APIs, traditional Chinese patent medicines and simple preparations, and health care products.
The company's flagship product, injection grade safflower yellow pigment, has been included in the national "863" plan and has won the National Key New Product Certificate, Zhejiang Province Patent Award Gold Award, Zhejiang Province Science and Technology Progress Second Prize. It is also the first Chinese medicine second-class protected variety. The Xinjiang safflower planting base has been rated as a "high-quality authentic medicinal material (safflower) demonstration base".
The company has fully passed the national new version of GMP certification, and some products have been certified by the US FDA, Japan PMDA, and South Korea KFDA. Among them, Cefoperam Hydrochloride is a standard product of the US Pharmacopeia. The company is currently focusing on tackling multiple new drug projects, one of which has been listed as a major national special project. It has applied for more than 80 domestic and foreign patents and has been granted 50 patents, including 9 foreign patents (4 US patents). The company has established a provincial-level postdoctoral workstation and research and development institutions in multiple universities in Beijing, Shanghai, Nanjing, and other places. It has been listed as a provincial-level high-tech enterprise research and development center.
